Respiratory distress syndrome (RDS) caused by surfactant deficiency remains one of the major reasons of morbi-mortality in preterm infants and affects 85% of preterm babies born less than 32 week gestational age (wGA). The strategy to manage RDS relies on the use of surfactant and non-invasive nasal ventilation, to limit tracheal mechanical ventilation. During recent years, surfactant administration through a thin catheter in spontaneously breathing preterm used in association with continuous positive airway pressure (CPAP) has emerged as a new approach for treating neonates with respiratory failure. The main objectives of Less Invasive Surfactant Administration (LISA) are to avoid endotracheal mechanical ventilation and its side effects including bronchopulmonary dysplasia. The LISA premedication procedure still under debate, because only 1 trial use analgesia or sedation during procedure. This reflects neonatologists concerns about side effects (apnea and the need for mechanical ventilation) of this premedication. This study aims to optimize sedation during LISA procedure by evaluating pain score with Ketamine or Protofol sedation, in Neonatal intensive care unit (NICU) patients with RDS.
Systematic reviews of the prospective studies performed suggest that among preterm infants, the use of LISA was associated with the lowest likelihood of the composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age when compared with the other ventilation strategies for preterm infants. Further studies are needed to optimize the indications and identify adequate strategies for premedication that preserve respiratory function and which limits pain and cardio-respiratory instability associated with laryngeal exposure without increasing risks of complications. According to a recent European survey, only 48% of neonatologists perform LISA with sedation. In a recent retrospective study, Dekker showed a more favorable COMFORTneo score with Propofol versus without, similar rates of intubation during LISA. Ketamine infusion has been used in several NICUs with few reported effects on respiratory function, but without publication. No prospective studies exist on LISA premedication. This study aims to optimize sedation during LISA in NICU patients with RDS. Comparing Ketamine and propofol sedation with rate of mechanical tracheal ventilation from the start of the LISA procedure up to 2 hours of life, in the NICU of Arnaud de Villeneuve University Hospital of Montpellier (France).
Study Type
OBSERVATIONAL
Enrollment
71
Uhmontpellier
Montpellier, France
Rate of mechanical ventilation (MV) from the start of the LISA procedure up to 2 hours of life
The Investigators would like to evaluating the need for MV within the time of the LISA procedure and up to 2 hours of life among preterm babies less than 30wGA
Time frame: 2 hours after LISA procedure
Cardiorespiratory parameters
Cardiorespiratory parameters before and at 5, 30 minutes after the drug injection: blood pressure
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
Cardiorespiratory parameters
Cardiorespiratory parameters before and at 5, 30 minutes after the drug injection: FiO2
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
Cardiorespiratory parameters
Cardiorespiratory parameters before and at 5, 30 minutes after the drug injection: heart rate
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
Rate of MV from the start of the LISA procedure up to 24 and 72 hours of life and causes of failure
Rate of MV from the start of the LISA procedure up to 24 and 72 hours of life and causes of failure (apnea, need surfactant)
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
To assess Neonatal morbidity at 36 wGA
Neonatal morbidity at 36 wGA
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
To assess mortality at 36 wGA
Mortality at 36 wGA
Time frame: 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.